More Stories

Informist, Saturday, Jan. 31, 2026

 

--Sun Pharma: Innovative pdt portfolio to drive growth in US, other mkts 

--Sun Pharma: Working to launch semaglutide in all strengths 

--CONTEXT: Comments from Sun Pharma in post-earnings analyst concall 

--Sun Pharma: Working to launch semaglutide in all strengths in India 

--Sun Pharma: To continue investing in R&D for generics, innovative pdts 

--Sun Pharma: May see smaller acquisitions in emerging markets going ahead 

--Sun Pharma: FY27 operating expenses may go up on innovative pdt launches 

--Sun Pharma: To add more sales force for semaglutide launch in India 

--Sun Pharma: Revlimid sales in Q3 quite small 

By Narayana Krishna and Arundathi A R

HYDERABAD/MUMBAI - The country's largest pharmaceutical company by sales Sun Pharmaceutical Industries Ltd. is gearing up to launch its version of obesity and weight loss drug generic semaglutide injection in various strengths, the company's management said in a post-earnings conference call on Saturday.

"We are excited to launch semaglutide in India on patent expiry. It will improve the access," Sun Pharma's management said. The patent for semaglutide, a key product in glucagon-like-peptide-1 category, is set to expire in India on Mar. 20. Sun Pharma had on Jan. 23 announced receiving approval from Drugs Controller General of India to manufacture and market a generic version of semaglutide injection under the brand name Noveltreat in five doses. The product is administered via an easy-to-use prefilled pen, designed to support convenient and accurate dosing.

 

Noveltreat will be available in five dose strengths - 0.25 milligram/0.5 millilitre, 0.5 milligram/0.5 millilitre, 1 milligram/0.5 millilitre, 1.7 milligram/0.75 millilitre, and 2.4 milligram/0.75 millilitre, with a maintenance dose of 2.4 milligram once weekly.

Sun Pharma said the company is recruiting some more sales force ahead of the proposed launch of semaglutide in India. 
For the December quarter, Sun Pharma reported a consolidated net profit of INR 33.69 billion, up 16% on year and 8% on quarter. The company's revenue was up 13.5% on year and 7.2% on quarter at INR 155.21 billion.

Sun Pharma's management said the innovative medicines segment will drive the future growth in the US as well as other key markets for the company going forward. For the December quarter, the specialty products segment, now renamed as the innovative medicines segment, reported total sales of $423 million. This includes a milestone income of $55 million. Excluding the milestone income, the revenue from the segment was up 13.2%.

 

The company declined to give any update on the possible launch of semaglutide oral tablet version. "We are well positioned here with an expected launch across both indications as well as all the strengths, presenting a comprehensive solution to the physicians as well as patients. Our brands will be made available in easy to use format and we have ensured sufficient supplies to meet the demand in India," the management said.

The company's management said it will continue to invest on research and development with a focus on developing products in global generics and innovative medicines segments. For the December quarter, the expenditure on research and development was at INR 8.93 billion, accounting for 5.8% of the total sales. Sun Pharma said as there are several innovative product launches lined up, its operating expenses may increase in 2026-27 (Apr-Mar). 

On inorganic strategy, Sun Pharma said its focus will be on innovative medicines in the US, while it will look at smaller acquisitions in emerging markets. Indicating that funding is not an issue for a suitable buyout, the management said it will raise debt if needed for acquisitions, declining to give any specific target or size.

"We have also consistently indicated that we want to remain disciplined about acquisitions. Our focus is on finding a way to grow our business organically at a rate so that we continue to be an attractive investment opportunity for shareholders. We would look at an acquisition only if we think that it can help us in terms of strengthening our long-term strategy capability," Sun Pharma management said. It said the contribution from generic cancer drug Revlimid was quite small and negligible in the December quarter. 

On Friday, Sun Pharma shares ended at INR 1,595.30 on the National Stock Exchange, up 0.4% from the previous close.  End

 

Edited by Vandana Hingorani

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.